Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand.
Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand.
复制标题
DOI：
10.1186/s12981-015-0053-z
复制
发表时间：
2015
影响因子：
2.2
通讯作者：
Adults and Adolescents Committee of the Thai National HIV Guidelines Working Group
中科院分区：
文献类型：
--
作者：
Manosuthi W;Ongwandee S;Bhakeecheep S;Leechawengwongs M;Ruxrungtham K;Phanuphak P;Hiransuthikul N;Ratanasuwan W;Chetchotisakd P;Tantisiriwat W;Kiertiburanakul S;Avihingsanon A;Sukkul A;Anekthananon T;Adults and Adolescents Committee of the Thai National HIV Guidelines Working Group
关于何时开始抗逆转录病毒治疗、最佳治疗方案、艾滋病毒合并感染与机会性感染的管理以及抗逆转录病毒治疗失败的管理，出现了新的证据。2014年的指南是由疾病控制部、公共卫生部（MOPH）和泰国艾滋病协会（TAS）合作制定的。该指南的主要变化之一包括建议启动ART，而不考虑CD 4细胞计数。然而，重点是在CD 4细胞计数高于500个细胞/mm 3时开始HAART是为了公共卫生，预防HIV传播和个人利益。对于CD 4细胞计数≤50个/mm 3或CD 4细胞计数>50个/mm 3的结核病合并感染患者，如果临床病情严重，应在开始结核病治疗后2周内开始ART治疗。初治患者首选的初始ART方案是依法韦仑联合替诺福韦和恩曲他滨或拉米夫定。血浆HIV病毒载量评估应每年进行两次，直到达到不可检测的结果;然后每年监测一次。每6个月监测一次CD 4细胞计数，直至CD 4细胞计数≥350 cells/mm 3，且血浆HIV病毒载量<50 copies/mL，此后每年监测一次。当接受ART治疗期间血浆HIV病毒载量> 1，000拷贝/mL时，需要进行HIV耐药基因型检测。在初始ART方案失败后，建议使用利托那韦加强的洛匹那韦或阿扎那韦联合优化的两种核苷类似物逆转录酶抑制剂。长期ART相关安全性监测也已纳入指南。本文的在线版本（doi：10.1186/s12981-015-0053-z）包含补充材料，可供授权用户使用。
New evidence has emerged regarding when to commence antiretroviral therapy (ART), optimal treatment regimens, management of HIV co-infection with opportunistic infections, and management of ART failure. The 2014 guidelines were developed by the collaborations of the Department of Disease Control, Ministry of Public Health (MOPH) and the Thai AIDS Society (TAS). One of the major changes in the guidelines included recommending to initiating ART irrespective of CD4 cell count. However, it is with an emphasis that commencing HAART at CD4 cell count above 500 cell/mm3 is for public health, in term of preventing HIV transmission and personal benefit. In tuberculosis co-infected patients with CD4 cell counts ≤50 cells/mm3 or with CD4 cell counts >50 cells/mm3 who have severe clinical disease, ART should be initiated within 2 weeks of starting tuberculosis treatment. The preferred initial ART regimen in treatment naïve patients is efavirenz combined with tenofovir and emtricitabine or lamivudine. Plasma HIV viral load assessment should be done twice a year until achieving undetectable results; and will then be monitored once a year. CD4 cell count should be monitored every 6 months until CD4 cell count ≥350 cells/mm3 and with plasma HIV viral load <50 copies/mL; then it should be monitored once a year afterward. HIV drug resistance genotypic test is indicated when plasma HIV viral load >1,000 copies/mL while on ART. Ritonavir-boosted lopinavir or atazanavir in combination with optimized two nucleoside-analogue reverse transcriptase inhibitors is recommended after initial ART regimen failure. Long-term ART-related safety monitoring has also been included in the guidelines. The online version of this article (doi:10.1186/s12981-015-0053-z) contains supplementary material, which is available to authorized users.
登录
查看更多内容
HAART启动和人类免疫缺陷病毒1型血清抗体的时机。
影响因子：
--
作者：
Funk, Michele Jonsson;Fusco, Jennifer S.;Cole, Stephen R.;Thomas, James C.;Porter, Kholoud;Kaufman, Jay S.;Davidian, Marie;White, Alice D.;Hartmann, Katherine E.;Eron, Joseph J., Jr.
通讯作者：
Eron, Joseph J., Jr.
DOI：
10.1056/nejmoa1013607
发表时间：
2011-10-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Havlir DV;Kendall MA;Ive P;Kumwenda J;Swindells S;Qasba SS;Luetkemeyer AF;Hogg E;Rooney JF;Wu X;Hosseinipour MC;Lalloo U;Veloso VG;Some FF;Kumarasamy N;Padayatchi N;Santos BR;Reid S;Hakim J;Mohapi L;Mugyenyi P;Sanchez J;Lama JR;Pape JW;Sanchez A;Asmelash A;Moko E;Sawe F;Andersen J;Sanne I;AIDS Clinical Trials Group Study A5221
通讯作者：
AIDS Clinical Trials Group Study A5221
影响因子：
6.4
作者：
Ioannidis, JPA;Abrams, EJ;Wilfert, CM
通讯作者：
Wilfert, CM
DOI：
10.1056/nejmoa1013911
发表时间：
2011-10-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Blanc FX;Sok T;Laureillard D;Borand L;Rekacewicz C;Nerrienet E;Madec Y;Marcy O;Chan S;Prak N;Kim C;Lak KK;Hak C;Dim B;Sin CI;Sun S;Guillard B;Sar B;Vong S;Fernandez M;Fox L;Delfraissy JF;Goldfeld AE;CAMELIA (ANRS 1295–CIPRA KH001) Study Team
通讯作者：
CAMELIA (ANRS 1295–CIPRA KH001) Study Team
影响因子：
56.3
作者：
Grinsztejn, Beatriz;Hosseinipour, Mina C.;Ribaudo, Heather J.;Swindells, Susan;Eron, Joseph;Chen, Ying Q.;Wang, Lei;Ou, San-San;Anderson, Maija;McCauley, Marybeth;Gamble, Theresa;Kumarasamy, Nagalingeshwaran;Hakim, James G.;Kumwenda, Johnstone;Pilotto, Jose H. S.;Godbole, Sheela V.;Chariyalertsak, Suwat;de Melo, Marineide Goncalves;Mayer, Kenneth H.;Eshleman, Susan H.;Piwowar-Manning, Estelle;Makhema, Joseph;Mills, Lisa A.;Panchia, Ravindre;Sanne, Ian;Gallant, Joel;Hoffman, Irving;Taha, Taha E.;Nielsen-Saines, Karin;Celentano, David;Essex, Max;Havlir, Diane;Cohen, Myron S.
通讯作者：
Cohen, Myron S.